Recent Events Effectively De-Risk Nuvilex, Inc.
BALTIMORE, Maryland, March 6, 2014 /PRNewswire/ --
Goldman Small Cap Research, a stock market research firm focused on the small cap and micro cap sectors, recently published a new research update on Nuvilex Inc. (OTCQB: NVLX). In the update, senior analyst Rob Goldman outlines his latest thesis.
"In our view, with institutional funding in place to a potential $27 million, Nuvilex has been transformed from an also-ran to a soon-to-be-prime time player in the biotech and medical marijuana arenas. Moreover, this funding agreement validates the Company's technology and effectively de-risks the stock."
Nuvilex is a biotechnology company with the rights to a novel cellulose-based live-cell encapsulation technology, called Cell-in-a-Box™, that will be used as a platform upon which treatments for several types of cancer, including advanced, inoperable pancreatic cancer, and diabetes are being built. Nuvilex's treatment for pancreatic cancer involves the use of the widely used anticancer prodrug, ifosfamide, together with encapsulated live cells that convert ifosfamide into its active or "cancer-killing" form. Nuvilex's subsidiary, Medical Marijuana Sciences, Inc., is dedicated to the development of cancer treatments based upon the well-known chemical constituents of marijuana. Nuvilex is exploring ways in which the Cell-in-a-Box™ technology may play a role in these efforts.
According to Goldman, now that an institution has validated the company, attention will be focused on fundamentals and a series of future milestones and executable events, which means a higher future valuation for the company and all three of its treatment categories: cancer, diabetes, and medicinal marijuana. Moreover, since all three categories address high profile, multi-billion dollar markets, the associated future valuation adjustments could be substantial as milestone events are executed.
About Goldman Small Cap Research: Led by former Piper Jaffray analyst and mutual fund manager Rob Goldman, Goldman Small Cap Research produces sponsored and non-sponsored small cap and micro cap stock research reports, articles, daily stock market blogs, and popular investment newsletters. Goldman Small Cap Research is not in any way affiliated with Goldman Sachs & Co.
A sponsored Goldman Small Cap Research report, update, newsletter, or article is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed. Please read all associated full disclosures, disclaimers, and analyst background on our website before investing. Neither Goldman Small Cap Research nor its parent is a registered investment adviser or broker-dealer with FINRA or any other agency. To download our research, view our disclosures, or for more information, visit http://www.goldmanresearch.com.
About Nuvilex, Inc. (OTCQB: NVLX): Nuvilex, Inc. is an international biotechnology firm focused on developing and preparing to commercialize treatments for cancer, diabetes and other diseases based on the live, therapeutically valuable, encapsulated cells platform. The Company is leveraging its cancer biology and clinical oncology research experience and expertise, particularly for use in oncology treatments, in addition to initiating oncology applications of medical marijuana. For more information visit: http://www.nuvilex.comhttp://us.lrd.yahoo.com/SIG=14q6n7t04/EXP=1305929345/**http%3A/http://www.globenewswire.com/newsroom/ctr%3Fd=218177%26l=7%26a=http://www.sunsienergies.com%26u=http%3A%2F%2Fhttp://www.sunsienergies.com%2F http://us.lrd.yahoo.com/SIG=14q6n7t04/EXP=1305929345/**http%3A/http://www.globenewswire.com/newsroom/ctr%3Fd=218177%26l=7%26a=http://www.sunsienergies.com%26u=http%3A%2F%2Fhttp://www.sunsienergies.com%2F.
Goldman Small Cap Research
Rob Goldman, Analyst
+1-410-609-7100
[email protected]
SOURCE Goldman Small Cap Research
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article